Existence, Stability and Optimal Drug Dosage for a Reaction-Diffusion System Arising in a Cancer Treatment

Jeff Morgan¹, Bao Quoc Tang^{*2}, and Hong-Ming Yin³

¹Department of Mathematics, University of Houston, Houston, USA. jjmorgan@uh.edu

²Department of Mathematics and Scientific Computing, University of Graz, Graz, Austria quoc.tang@uni-graz.at

³Department of Mathematics and Statistics, Washington State University, Pullman, USA hyin@wsu.edu

Abstract

In this paper, a reaction-diffusion system modeling injection of a chemotherapeutic drug on the surface of a living tissue during a treatment for cancer patients is studied. The system describes the interaction of the chemotherapeutic drug and the normal, tumor and immune cells. We first establish well-posedness for the nonlinear reaction-diffusion system, then investigate the long-time behavior of solutions. Particularly, it is shown that the cancer cells will be eliminated assuming that its reproduction rate is sufficiently small in a short time period in each treatment interval. The analysis is then essentially exploited to study an optimal drug injection rate problem during a chemotherapeutic drug treatment for tumor cells, which is formulated as an optimal boundary control problem with constraints. For this, we show that the existence of an optimal drug injection rate through the boundary, and derive the first-order optimality condition.

AMS Subject Classification: 35E20, 35K40, 35K57, 49J20, 92C50.

Keywords: Modeling cells and drug interaction; Nonlinear reaction-diffusion system; Optimal injection rate; Optimal boundary control problem.

1 Introduction

Cancer is a major human disease in modern society, for which finding a cure is a great challenge for scientists and medical practitioners. One of the important tasks in fighting this type of disease is to understand how a medical drug interacts with normal, cancer and immune cells. Toward this goal, many researchers have proposed mathematical models based on a system of ordinary differential equations (ODE model) (see, for examples, [Ada93, BP00, FGP99, KP98, OS99, Jac15]). One of the popular mathematical models is the following ODE system which describes the interaction of normal, tumor, immune cells and a medical drug, whose concentrations are denoted by $\tilde{N}(t)$, $\tilde{T}(t)$, $\tilde{I}(t)$, and

^{*}Corresponding author.

 $\tilde{U}(t)$, respectively, (see [BP00, KP98, OS99]):

$$\begin{split} \tilde{N}_{t} &= r_{1}\tilde{N}(1 - b_{1}\tilde{N}) - c_{4}\tilde{T}\tilde{N} - a_{3}(1 - e^{-\tilde{U}})\tilde{N}, \\ \tilde{T}_{t} &= r_{2}\tilde{T}(1 - b_{2}\tilde{T}) - c_{2}\tilde{I}\tilde{T} - c_{3}\tilde{T}\tilde{N} - a_{2}(1 - e^{-\tilde{U}})\tilde{T}, \\ \tilde{I}_{t} &= s(t) + \frac{\rho\tilde{I}\tilde{T}}{\alpha + \tilde{T}} - c_{1}\tilde{I}\tilde{T} - k_{1}\tilde{I} - a_{1}(1 - e^{-\tilde{U}})\tilde{I}, \\ \tilde{U}_{t} &= v(t) - k_{2}\tilde{U}. \end{split}$$
(1)

Here s(t) and v(t) are the injection rates of immune cell and the medical drug, respectively. The values of various parameters in the ODE system (1) are observed and measured in medical clinics and research laboratories (see data in [KMTP94]). However, it is well observed in experiments and clinical data ([RCM07]) that cells will diffuse to the surrounding area of living tissue (see Ansarizadeh-Singh-Richards [ASR17], Bellomo-Preziosi [BP00], Friedman [Fri05], Friedman-Kim [FK11], Lou-Ni [LN96], Roose-Chapman-Maini[RCM07], Wodarz-Komarova [Jac15]). One can also find many more references in an excellent survey article which gave a summary of various models up to the year 2010 by J. S. Lowengrub, etc. [LFJ⁺09]. Therefore, one needs to take a diffusion process into consideration in the mathematical modelling. This fact leads to the following PDE model:

$$\begin{split} \widehat{N}_{t} &= \nabla \cdot (d_{1}(x,t)\nabla \widehat{N}) + \widehat{F}_{1}(\widehat{N},\widehat{T},\widehat{I},\widehat{U}), \quad (x,t) \in Q_{\tilde{t}}, \\ \widehat{T}_{t} &= \nabla \cdot (d_{2}(x,t)\nabla \widehat{T}) + \widehat{F}_{2}(\widehat{N},\widehat{T},\widehat{I},\widehat{U}), \quad (x,t) \in Q_{\tilde{t}}, \\ \widehat{I}_{t} &= \nabla \cdot (d_{3}(x,t)\nabla \widehat{I}) + \widehat{F}_{3}(\widehat{N},\widehat{T},\widehat{I},\widehat{U}), \quad (x,t) \in Q_{\tilde{t}}, \\ \widehat{U}_{t} &= \nabla \cdot (d_{4}(x,t)\nabla \widehat{U}) + \widehat{F}_{4}(\widehat{N},\widehat{T},\widehat{I},\widehat{U}), \quad (x,t) \in Q_{\tilde{t}}, \end{split}$$

$$(2)$$

where $d_i(x,t)$ represents the space-time dependent diffusion coefficient for each type of component, $Q_{\tilde{t}} = \Omega \times (0,\tilde{t})$ for $\tilde{t} > 0$ and Ω is a bounded domain in \mathbb{R}^n with C^2 -boundary $S = \partial \Omega$. The interaction functions $\hat{F}_1, \hat{F}_2, \hat{F}_3$ and \hat{F}_4 are similar to those in the ODE model (1) (see [CSS92, KMTP94, KP98]):

$$\begin{split} \widehat{F}_{1}(\widehat{N},\widehat{T},\widehat{I},\widehat{U}) &= r_{1}\widehat{N}(1-b_{1}\widehat{N}) - c_{4}\widehat{T}\widehat{N} - a_{3}(1-e^{-\widehat{U}})\widehat{N}, \\ \widehat{F}_{2}(\widehat{N},\widehat{T},\widehat{I},\widehat{U}) &= r_{2}\widehat{T}(1-b_{2}\widehat{T}) - c_{2}\widehat{I}\widehat{T} - c_{3}\widehat{T}\widehat{N} - a_{2}(1-e^{-\widehat{U}})\widehat{T} \\ \widehat{F}_{3}(\widehat{N},\widehat{T},\widehat{I},\widehat{U}) &= s(x,t) + \frac{\rho\widehat{I}\widehat{T}}{\alpha+\widehat{T}} - c_{1}\widehat{I}\widehat{T} - k_{1}\widehat{I} - a_{1}(1-e^{-\widehat{U}})\widehat{I}, \\ \widehat{F}_{4}(\widehat{N},\widehat{T},\widehat{I},\widehat{U}) &= v(x,t) - k_{2}\widehat{U}. \end{split}$$

The various parameters in \hat{F}_i are derived for cell-growth models from the clinical data (see [KMTP94]) and s(x,t) is the injection rate of immune cells while v(x,t) represents the injection rate of external chemotherapeutic drug. We remark that s(x,t) can be considered a combination of the natural growth and an injection, and as a result, s(x,t) could be a considered a control variable. However, in this work we will treat s(x,t) as given and focus only on the drug dosage rate v(x,t) as a control.

For the ODE model (1), De Pillis and Radunskaya in 2003 ([DPR03]) illustrated a very interesting dynamic of the interaction among normal, tumor and immune cells under the treatment of the chemotherapeutic drug. They obtained a range of parameters for which the steady-state solution of the system (1) is stable or unstable. Particularly, they analyzed how the region of tumor cells changes under the influence of immune cell and chemotherapeutic drug. For the PDE model (2), Ansarizadeh-Singh-Richards ([ASR17]) in 2017 studied the dynamics of the solution in one-space dimension. They obtained similar dynamical stability results for the range of various parameters as the ODE model (1). Particularly, they proved the Jeff's phenomenon (see [KMTP94]) observed in clinical data, which suggests that a tumor might continue to grow after treatment, and then, some time after treatment has ceased, begin to decrease in size, see [DPR01]. Another interesting result was demonstrated in [ASR17], where they numerically showed that in order to slow the growth of the tumor, the chemotherapeutic drug should be injected near the invasive front of the tumor (optimal location).

Recently, the author of [Yin22] studied the PDE model (2) for any space dimension. For the nonlinear system (2) subject to appropriate initial-boundary conditions, the global existence and uniqueness are established in [Yin22]. Particularly, it is shown that under certain conditions the cancer cells will be eliminated after a long-time treatment. Moreover, the author of [Yin22] also studied the optimal drug dosage problem and proved that there exists an optimal amount of drug during a chemotherapeutic drug treatment for cancer patients.

In this paper we study extended formulation of these existing models, where we assume that the drug will be injected through the surface of a living tissue at periodic intervals. This will definitely be a more effective method during a chemotherapeutic drug treatment. For the corresponding nonlinear reaction-diffusion system, we first prove that there exists a unique global weak solution which is uniformly bounded. Then the asymptotic behavior of the solution to is studied. In particular, it is shown that for the extinction of tumor cells, it is sufficient to require that the reproduction rate of tumor cells is small enough in a short period during each treatment interval (see assumption (H5)). This somehow aligns well with the observed Jeff's phenomenon [KMTP94]. Next we turn our attention to finding the optimal drug injection rate during a chemotherapeutic treatment for cancer patients. The resulting optimal control problem is complicated due to certain constraints that the number of normal and immune cells have to remain above a certain level. We use a penalty method to prove that there exists an optimal drug injection rate for the problem. Moreover, we derive the first order optimality condition for the optimal solution. This condition will provide an effective way to calculate the numerical solution for the optimal control problem.

We end this introduction section by emphasizing that our paper aims at a thorough well-posedness and stability analysis for a RDS model of the form (3)-(4), which arises from cancer treatment. These analysis are then exploited to investigate an boundary optimal control problem with constraints. There are plenty of papers modeling tumor-immune actions, where the reaction terms are somewhat different from what is considered in the current paper, which is due specific and different mechanisms, see e.g. [ATH⁺24, ESJY21, LF17] and references therein. We believe that our methods and analysis here can be well adapted to study to those models, and this will be investigated in future research.

The paper is organized as follows. In section 2, we describe the generalized PDE model for the above problem. Subsections 2.1 and 2.2 are devoted to the global existence, uniqueness of solutions and their large time stability, respectively. In Section 3 we investigate the optimal control problem where we prove the existence of an optimal drug dosage during a chemotherapeutic treatment in subsection 3.1 and derive the optimality condition in subsection 3.2. Some concluding remarks are given in the final Section 4.

2 The Generalized Mathematical Model

In the derivation of the mathematical model, we assume that the concentration for each type of cells satisfies a logistic growth model. Moreover, we assume the interaction between various cells and chemotherapeutic drug have the same pattern as the ODE model (1) with the modification that the drug treatment occurs on the boundary, and the immune cells also satisfy a logistic growth. With these assumptions, we see that the concentrations of normal, tumor and immune cells satisfy the following reaction-diffusion system¹:

$$\begin{cases} N_{t} = \nabla \cdot (d_{1}(x, t, N) \nabla N) + F_{1}(N, T, I, U), & (x, t) \in Q_{\tilde{t}}, \\ T_{t} = \nabla \cdot (d_{2}(x, t, T) \nabla T) + F_{2}(N, T, I, U), & (x, t) \in Q_{\tilde{t}}, \\ I_{t} = \nabla \cdot (d_{3}(x, t, I) \nabla I) + F_{3}(N, T, I, U), & (x, t) \in Q_{\tilde{t}}, \\ U_{t} = \nabla \cdot (d_{4}(x, t, U) \nabla U) + F_{4}(N, T, I, U), & (x, t) \in Q_{\tilde{t}}, \end{cases}$$
(3)

where the nonlinearities F_1, F_2, F_3 and F_4 are given as follows:

$$F_{1}(N,T,I,U) = r_{1}N(1-b_{1}N) - c_{4}TN - a_{3}(1-e^{-U})N,$$

$$F_{2}(N,T,I,U) = r_{2}T(1-b_{2}T) - c_{2}IT - c_{3}TN - a_{2}(1-e^{-U})T,$$

$$F_{3}(N,T,I,U) = r_{3}I(1-b_{3}I) + s(x,t) + \frac{\rho IT}{\alpha+T} - c_{1}IT - k_{1}I - a_{1}(1-e^{-U})I,$$

$$F_{4}(N,T,I,U) = -k_{2}(x,t,N,T,I,U)U,$$
(4)

where $r_i = r_i(x, t, N, T, I, U)$, i = 1, 2, 3, is the "coefficient" of the logistic growth for each type of cells, $1/b_i$, i = 1, 2, 3, represents the reciprocal of the maximum capacity, and the consumption rate k_2 for the medical drug is assumed to depend on space-time variables and all types of cells.

From clinic practices, the chemotherapeutic drug treatment for patients must be stopped if the concentration of normal cells is below a certain level. Therefore, the drug injection should be stopped if the concentration of normal cells is smaller than a certain level, say, $a_0 > 0$, where naturally we impose $0 < a_0 < 1/b_1$ which is the capacity of normal cell density. To reflect this fact, we introduce a Heaviside-like function H(s) which is a C^1 -function with H(s) = 1 if $s \ge \delta$ for some small $\delta > 0$ and H(s) = 0 if s < 0. The drug injection rate v(x, t) through the boundary is given by

$$d_4 \nabla_{\nu} U(x,t) = v(x,t) H(N-a_0), \ (x,t) \in S \times (0,\infty).$$

Therefore, for the system (3) we prescribe the following initial and boundary conditions:

$$\begin{cases} Z(x,0) = Z_0(x), & Z \in \{N,T,I,U\}, \ x \in \Omega, \\ \nabla_{\nu}Z(x,t) = 0, & Z \in \{N,T,I\}, \ (x,t) \in S \times (0,\tilde{t}), \\ d_4 \nabla_{\nu}U(x,t)) = v(x,t)H(N-a_0), \quad (x,t) \in S \times (0,\tilde{t}) \end{cases}$$
(5)

where ν is the outward unit normal on S and ∇_{ν} represents the normal derivative on S.

It is our aim to find an optimal drug injection rate v(x, t) through the boundary S during a chemotherapeutic drug treatment for cancer patients, where the underlying state variables satisfy the nonlinear

¹It is worthwhile to mention that all results in this paper can be extended to the case where the diffusion coefficients depend on all concentrations, i.e. $d_i = d_i(x, t, N, T, I, U)$. We leave the details for the interested reader.

reaction-diffusion system (3)-(5), in the sense that a cost function involving the total mass of tumor cells is minimized. This leads us to first study the well-posedness for the nonlinear reaction-diffusion system (3)-(5). These results are themselves of theoretical interest and also provide the tools in the study of the optimal control problem.

In the following subsection, we briefly show that the system (3)–(5) has a unique global weak solution which is uniformly bounded in time. Moreover, the weak solution is also regular if all of the coefficients in the system (3) are smooth. We also prove in subsection 2.2 that the solution to the system (3)–(5) converges to the solution of the corresponding steady-state system under certain conditions. In the sequel, we denote $\mathbb{R}_+ = [0, \infty)$ and we use the following function spaces

 $L^{\infty}(Q_{\tilde{t}}) := \{ u : Q_{\tilde{t}} \to \mathbb{R} \mid \text{ess sup}_{Q_{\tilde{t}}} | u(x,t) | < +\infty \},$

$$C^{\alpha,\frac{\alpha}{2}}(\bar{Q}) := \{ u : \overline{Q_{\tilde{t}}} \to \mathbb{R} \mid u(\cdot,t) \in C^{\alpha}(\bar{\Omega}) \, \forall t \in [0,\tilde{t}] \text{ and } u(x,\cdot) \in C^{\frac{\alpha}{2}}([0,\tilde{t}]) \, \forall x \in \bar{\Omega} \}.$$

The space $V_2(Q_{\tilde{t}})$ is defined through the norm

$$\|u\|_{V_2(Q_{ ilde{t}})} := \max_{t \in [0, ilde{t}]} \|u(t)\|_{L^2(\Omega)} + \|
abla u\|_{L^2(Q_{ ilde{t}})}.$$

For brevity, a vector function $\mathbf{f} = (f_1, f_2, \dots, f_m)$ belonging in a product space B^m simply means each component is in the space B, and the exponent m is sometimes omitted.

2.1 Global Existence, Uniqueness and Regularity

In this section we show that the problem (3)-(5) admits a unique global non-negative bounded weak solution under certain minimum conditions on the coefficients and known data.

The following basic conditions are assumed throughout this section.

(H1) Let $d_i(x,t,z)$, i = 1, ..., 4, be such that $d_i(x,t,\cdot) \in C^1(\mathbb{R}_+)$ uniformly in $(x,t) \in Q_{\tilde{t}}$, $d_i(\cdot, \cdot, z) \in L^{\infty}(Q_{\tilde{t}})$ for each $z \in \mathbb{R}$ and $\tilde{t} > 0$, and there exists a constant δ_0 such that

$$0 < \delta_0 \le d_i(x, t, z), \qquad (x, t, z) \in Q_{\tilde{t}} \times \mathbb{R}_+, \ i = 1, \cdots, 4.$$

Also, for each $\tilde{t} > 0$, $r_i(x, t, N, T, I, U) \in L^{\infty}(Q_{\tilde{t}} \times \mathbb{R}^4_+)$ is locally Lipschitz continuous w.r.t. N, T, I, U uniformly in $(x, t) \in Q_{\tilde{t}}$, and there exist constants r_0 and R_0 such that

$$0 < r_0 \le r_i(x, t, N, T, I, U) \le R_0$$

for all $(x, t, N, T, I, U) \in Q_{\tilde{t}} \times \mathbb{R}^4_+$.

(H2) For each $\tilde{t} > 0$ the functions v(x,t) and s(x,t) are nonnegative a.e. in $S \times (0,\tilde{t})$ and $Q_{\tilde{t}}$, respectively, and there exists a constant A_1 such that

$$||v||_{L^{\infty}(S \times (0,\tilde{t}))} + ||s||_{L^{\infty}(Q_{\tilde{t}}))} \le A_{1}$$

In addition, the Heaviside-like function $H(z) \in C^1(\mathbb{R})$ is increasing and satisfies $H(z) = 0, z \in (-\infty, 0]$ and H(z) = 1 in $[\delta, \infty)$ for a small constant $\delta > 0$.

(H3) The initial data $(N_0, T_0, I_0, U_0) \in L^{\infty}(\Omega)$ are nonnegative.

(H4) The parameters a_i, c_i and k_1, α, ρ in the system (3) are positive. Moreover, $k_2 \in L^{\infty}(Q_{\tilde{t}} \times \mathbb{R}^4_+)$ and $k_2(x, t, N, T, I, U) \ge k_0 > 0$ for some constant k_0 .

We start with the definition of a weak solution to (3).

Definition 2.1. A non-negative quadruple (N, T, I, U) is called a non-negative weak solution to (3)– (5) on $Q_{\tilde{t}} = \Omega \times (0, \tilde{t})$ if for any $Z \in \{N, T, I, U\}$,

$$egin{aligned} Z \in V_2(Q) \cap L^\infty(Q_{ ilde{t}}), \ \partial_t Z \in L^2(0, ilde{t};(H^1(\Omega))^*), \ & Z(x,0) = Z_0(x), \quad a.e. \ x \in \Omega, \end{aligned}$$

and for any smooth test function φ it holds for $Z \in \{N, T, I\}$, i = 1, 2, 3,

$$\iint_{Q_{\tilde{t}}} \partial_t Z \varphi dx dt + \iint_{Q_{\tilde{t}}} d_i(x, t, Z) \nabla Z \cdot \nabla \varphi dx dt = \iint_{Q_{\tilde{t}}} F_i(N, T, I, U) \varphi dx dt,$$

and

$$\begin{split} &\iint_{Q_{\tilde{t}}} \partial_t U \varphi dx dt + \iint_{Q_{\tilde{t}}} d_4(x,t,U) \nabla U \cdot \nabla \varphi dx dt \\ &= \iint_{S \times (0,\tilde{t})} v H(N-a_0) \varphi d\mathcal{H} dt + \iint_{Q_{\tilde{t}}} F_4(N,T,I,U) \varphi dx dt. \end{split}$$

A weak solution is called global when it is a weak solution on $Q_{\tilde{t}}$ for any $\tilde{t} > 0$.

The main result of this subsection is the global existence and boundedness of the solution to (3)–(5). To do that, we use the following lemma which can be of independent interest. The proof of this lemma follows from [Ali79], and is postponed to the Appendix A for completeness.

Lemma 2.2. Let $t_0 > 0$ and $0 \le u \in L^{\infty}(\Omega \times (0, t_0)) \times L^2(0, t_0; H^1(\Omega))$ satisfy

$$\begin{cases} \partial_t u \leq \nabla \cdot (\delta(x,t,u)\nabla u) + au + b, & x \in \Omega, 0 < t < t_0, \\ \delta(x,t,u)\nabla u \cdot \eta \leq cu + d(x,t), & x \in \partial\Omega, 0 < t < t_0, \\ u(x,0) = u_0(x), & x \in \Omega, \end{cases}$$
(6)

in the weak sense, with $u_0 \in L^{\infty}(\Omega)$, $0 < \delta_0 \leq \delta(x,t,z)$ for all $(x,t,z) \in \Omega \times (0,t_0) \times \mathbb{R}$, $d \in L^{\infty}(S \times (0,t_0))$, and $a,b,c \geq 0$. Then there is a constant L > 0 dependent only on $\delta_0, a, b, c, \Omega$, $\|d\|_{L^{\infty}(S \times (0,t_0))}$, $\|u_0\|_{L^{\infty}(\Omega)}$, and $\|u\|_{L^{\infty}(0,t_0;L^1(\Omega))}$, but not explicitly on t_0 , such that

$$\|u\|_{L^{\infty}(\Omega\times(0,t_0))} \leq L.$$

Theorem 2.3. Assume (H1)-(H4). There exists a global non-negative, bounded weak solution to (3), *i.e.*

$$||Z||_{L^{\infty}(\Omega \times (0,\tilde{t}))} < \infty, \quad \forall Z \in \{N, T, I, U\}, \quad \forall \tilde{t} > 0$$

In addition, if all functions d_i, r_i, k_2, s, v are smooth and the initial data satisfy the compatibility conditions

$$\nabla_{\nu} Z_0(x) = 0, \ Z \in \{N, T, I\}, \ x \in S,
d_4 \nabla_{\nu} U_0(x) = v(x, 0) H(N_0(x) - a_0), \ x \in S,$$
(7)

then the solution is classical in $Q_{\tilde{t}}$ for each $\tilde{t} > 0$.

Moreover, if for any $z \in \mathbb{R}$, and any $\tilde{t} > 0$, the mapping $\Omega \times [0, \tilde{t}] \ni (x, t) \to d_i(x, t, z)$ is Hölder continuous in each component, then the aforementioned weak solution is unique.

Proof. Let $\varepsilon > 0$. We consider the following approximate system with $Z_{\varepsilon} \in \{N_{\varepsilon}, T_{\varepsilon}, I_{\varepsilon}, U_{\varepsilon}\}$

$$\begin{cases} \partial_t Z_{\varepsilon} - \nabla \cdot (d_i^{\varepsilon}(x, t, Z_{\varepsilon}) \nabla Z_{\varepsilon}) = F_i^{\varepsilon}(N_{\varepsilon}, T_{\varepsilon}, I_{\varepsilon}, U_{\varepsilon}), & (x, t) \in Q_{\tilde{t}}, \\ \nabla N_{\varepsilon} \cdot \nu = \nabla T_{\varepsilon} \cdot \nu = \nabla I_{\varepsilon} \cdot \nu = 0, & (x, t) \in S \times (0, \tilde{t}), \\ d_4^{\varepsilon} \nabla U_{\varepsilon} \cdot \nu = v(x, t) H(N_{\varepsilon} - a_0), & (x, t) \in S \times (0, \tilde{t}), \\ Z_{\varepsilon}(x, 0) = Z_{\varepsilon, 0}(x), & x \in \Omega, \end{cases}$$

$$(8)$$

where $d_i^{\varepsilon}(x, t, \cdot) \in C^{\infty}(Q \times \mathbb{R})$ satisfy

$$\frac{\delta_0}{2} \le d_i^{\varepsilon}(x,t,z) \le 2A_2, \qquad (x,t,z) \in Q_{\tilde{t}} \times \mathbb{R}_+, \ i = 1,\dots,4,$$

$$\sup_{z \in \mathbb{R}} \|d_i^{\varepsilon}(\cdot,\cdot,z) - d_i(\cdot,\cdot,z)\|_{L^{\infty}(Q_{\tilde{t}})} \to 0 \quad \text{and} \quad \sup_{(x,t) \in Q_{\tilde{t}}} \|d_i^{\varepsilon}(x,t,\cdot) - d_i(x,t,\cdot)\|_{C^1(\mathbb{R}_+)} \to 0$$
(9)

as $\varepsilon \to 0$, with $A_2 = \max_{i=1,\dots,4} \sup_{s \in \mathbb{R}_+} \|d_i(\cdot,\cdot,z)\|_{L^{\infty}(Q_{\tilde{t}})}$, the approximated nonlinearities given by

$$F_i^{\varepsilon}(N_{\varepsilon}, T_{\varepsilon}, I_{\varepsilon}, U_{\varepsilon}) := \frac{F_i(N_{\varepsilon}, T_{\varepsilon}, I_{\varepsilon}, U_{\varepsilon})}{1 + \varepsilon \sum_{j=1}^4 |F_j(N_{\varepsilon}, T_{\varepsilon}, I_{\varepsilon}, U_{\varepsilon})|},$$

and the initial data $0 \leq Z_{\varepsilon,0} \in (C^{\infty}(\overline{\Omega}))^4$ satisfies the compatibility (7) and approximates Z_0 in $(L^{\infty}(\Omega))^4$. Since the diffusion coefficients are smooth and the approximated nonlinearities are bounded, the existence of a global weak solution to (8) can be obtained using the standard Galerkin method. Moreover, this weak solution is unique, see e.g. [Nit13]. To show the non-negativity of the approximated solution, we consider the auxiliary system

$$\partial_t Z_{\varepsilon} - \nabla \cdot (d_i^{\varepsilon}(x, t, Z_{\varepsilon}) \nabla Z_{\varepsilon}) = F_i^{\varepsilon}(N_{\varepsilon}^+, T_{\varepsilon}^+, I_{\varepsilon}^+, U_{\varepsilon}^+)$$

with the same boundary conditions and initial data as in (8), where $z^+ = \max\{z, 0\}$. The global existence of a weak solution to this system follows the same way as for (8) since the nonlinearities still have all the properties as in (8). By multiplying this equation by $Z_{\varepsilon}^- = \min\{Z_{\varepsilon}, 0\}$ and using the explicit forms of the nonlinearities in (4) which yield $F_i^{\varepsilon}(N_{\varepsilon}^+, T_{\varepsilon}^+, I_{\varepsilon}^+, U_{\varepsilon}^+)Z_{\varepsilon}^- \leq 0$, we have

$$\frac{1}{2}\frac{d}{dt}\|Z_{\varepsilon}^{-}\|_{L^{2}(\Omega)}^{2} + \delta_{0}\|\nabla Z_{\varepsilon}^{-}\|_{L^{2}(\Omega)}^{2} \le 0$$

and consequently

$$||Z_{\varepsilon}^{-}(t)||_{L^{2}(\Omega)}^{2} \leq ||Z_{\varepsilon,0}^{-}||_{L^{2}(\Omega)}^{2}.$$

This shows $Z_{\varepsilon}(t) \ge 0$ for all t > 0 thanks to the non-negativity of the initial data. Now by uniqueness we obtain that the global weak solution to (8) is non-negative.

We now turn to uniform-in- ε estimates of solutions to (8). Let $0 < t_0 < \tilde{t}$. From the equation of U_{ε} we have

$$\left\{egin{aligned} &\partial_t U_arepsilon -
abla \cdot (d_4(x,t,U_arepsilon)
abla U_arepsilon) &\leq -k_0 U_arepsilon, & x\in\Omega, \ &d_4(x,t,U_arepsilon)
abla U_arepsilon\cdot\eta = v(x,t)H(N_arepsilon-a_0), & x\in S, \ &U_arepsilon(x,0) = U_{arepsilon,0}, & x\in\Omega. \end{aligned}
ight.$$

By integrating over Ω , we have

$$\frac{d}{dt}\int_{\Omega}U_{\varepsilon}dx+k_{0}\int_{\Omega}U_{\varepsilon}dx\leq\int_{S}v(x,t)H(N_{\varepsilon}-a_{0})d\mathcal{H}\leq C(H,|S|)\|v(t)\|_{L^{\infty}(S)},$$

which leads to

$$\|U_{\varepsilon}\|_{L^{\infty}(0,T;L^{1}(\Omega))} \leq \|U_{\varepsilon,0}\|_{L^{1}(\Omega)} + C(H,|S|)\|v\|_{L^{\infty}(S\times(0,t_{0}))}.$$

Now, we can apply Lemma 2.2, we have

$$\|U_{\varepsilon}\|_{L^{\infty}(\Omega\times(0,t_{0}))} \leq C(\|U_{0}\|_{L^{\infty}(\Omega)}, H, |S|, \|v\|_{L^{\infty}(S\times(0,t_{0}))}).$$
(10)

By using similar arguments for the equations of $N_{\varepsilon}, T_{\varepsilon}, I_{\varepsilon}$ with the remark that all superlinear order terms have non-positive sign (see (4)), we get

$$||Z_{\varepsilon}(t)||_{L^{\infty}(\Omega)} \le C(\tilde{t}) < +\infty \quad \forall t > 0, \ Z \in \{N, T, I\}.$$
(11)

By (10) and (11), $||F_i(N_{\varepsilon}, T_{\varepsilon}, I_{\varepsilon}, U_{\varepsilon})||_{L^2(Q_{\tilde{t}})} \leq C$, and standard arguments give

$$||Z_{\varepsilon}||_{V(Q)} \le C, \quad Z_{\varepsilon} \in \{N_{\varepsilon}, T_{\varepsilon}, I_{\varepsilon}, U_{\varepsilon}\}.$$

By Aubin-Lions lemma, we can extract a subsequence, which is still denoted by $(N_{\varepsilon}, T_{\varepsilon}, I_{\varepsilon}, U_{\varepsilon})$ such that

 $Z_{\varepsilon} \longrightarrow Z$ strongly in $L^2(Q_{\tilde{t}})$ and weakly in $L^2(0, \tilde{t}; H^1(\Omega)), \quad Z \in \{N, T, I, U\}.$

For a smooth test function, we can then pass to the limit $\varepsilon \to 0$ in the equations

$$\iint_{Q_{\tilde{t}}} \partial_t Z_{\varepsilon} \varphi dx dt + \iint_{Q_{\tilde{t}}} d_i^{\varepsilon}(x, t, Z_{\varepsilon}) \nabla Z_{\varepsilon} \cdot \nabla \varphi dx dt = \iint_{Q_{\tilde{t}}} F_i^{\varepsilon}(N_{\varepsilon}, T_{\varepsilon}, I_{\varepsilon}, U_{\varepsilon}) \varphi dx dt$$

for $Z_{\varepsilon} \in \{N_{\varepsilon}, T_{\varepsilon}, I_{\varepsilon}\}, i = 1, \dots, 3$, and

$$\begin{split} &\iint_{Q_{\tilde{t}}} \partial_t U_{\varepsilon} \varphi dx dt + \iint_{Q_{\tilde{t}}} d_4^{\varepsilon}(x,t,U_{\varepsilon}) \nabla U_{\varepsilon} \cdot \nabla \varphi dx dt \\ &= \iint_{S \times (0,\tilde{t})} v H(N_{\varepsilon} - a_0) \varphi d\mathcal{H} dt + \iint_{Q_{\tilde{t}}} F_4^{\varepsilon}(N_{\varepsilon},T_{\varepsilon},I_{\varepsilon},U_{\varepsilon}) \varphi dx dt, \end{split}$$

to finally conclude that (N, T, I, U) is a global non-negative weak solution to (3).

If the diffusion coefficients are Hölder continuous in x and t, then the uniqueness of the weak solution follows from [Nit13].

The standard regularity theory for parabolic equations ([Eva10, Lie96, LSU68]) implies that if all functions and coefficients in (3) are smooth, and the initial data are smooth and satisfy the compatibility conditions (7), then the solution is also classical.

2.2 Stability analysis

In this subsection, we first investigate the uniform-in-time boundedness of the weak solution constructed in the previous subsection. Recall that from (H2) we know v and s are only bounded on each finite time interval. For the solutions to be bounded uniformly in time, we need that the constant A_1 in (H2) to be time independent, i.e.

$$||v||_{L^{\infty}(S \times [0,\infty))} + ||s||_{L^{\infty}(\Omega \times [0,\infty))} \le A_1.$$

Proposition 2.4. Assume (H1)–(H4) where A_1 in (H2) is time independent. Then the weak solution to (3) obtained in Theorem 2.3 is bounded uniformly in time, i.e.

$$\sup_{t \ge 0} \|Z(t)\|_{L^{\infty}(\Omega)} \le M < +\infty, \quad \forall Z \in \{N, I, T, U\}.$$

Proof. By the comparison principle, thanks to the non-negativity of solutions, we immediately have

$$\limsup_{t\to\infty} \|N(t)\|_{L^{\infty}(\Omega)} \leq \frac{1}{b_1}, \quad \text{ and } \quad \limsup_{t\to\infty} \|T(t)\|_{L^{\infty}(\Omega)} \leq \frac{1}{b_2}.$$

For the bound of U, we first show that $||U||_{L^{\infty}(0,t_0;L^1(\Omega))}$ is bounded uniformly in t_0 . By integrating the equation of U in Ω , we get

$$\frac{d}{dt}\int_{\Omega}U(x,t)dx+k_0\int_{\Omega}U(x,t)dx=\int_{S}v(x,t)H(N-a_0)dx\leq C|S|\|v(t)\|_{L^{\infty}(S)}.$$

The classical Gronwall inequality gives

$$\int_{\Omega} U(x,t) dx \le e^{-k_0 t} \int_{\Omega} U_0(x) dx + C|S| \sup_{t \ge 0} \|v(t)\|_{L^{\infty}(S)} \frac{1}{k_0}$$

which is the desired bound of U. Now by applying Lemma 2.2, we obtain

$$\limsup_{t \to \infty} \|U(t)\|_{L^{\infty}(\Omega)} < +\infty$$

For the boundedness of I, we first observe from (4), (H1) and (H2) that

$$F_3(N, T, I, U) \le R_0 I - r_0 b_3 I^2 + A_1 + \rho I \le \lambda_1 I - \lambda_2 I^2 + A_1 \le A - \lambda I$$

for some $\lambda_1, \lambda_2, \widetilde{A}, \widetilde{\lambda} > 0$. By the comparison principle

$$\limsup_{t \to \infty} \|I(t)\|_{L^{\infty}(\Omega)} < +\infty$$

which finishes the proof of the Proposition.

Corollary 2.5. Under assumptions (H1)–(H4) where A_1 in (H2) is time independent, there exists a maximal attractor \mathcal{A} in $L^{\infty}_{+}(\Omega)$ for the semigroup $\{S(t)\}_{t\geq 0}$ defined by $S(t) : (N_0, T_0, I_0, U_0) \mapsto$ (N(t), T(t), I(t), U(t)) where (N, T, I, U) is the solution to the system (3)–(5).

Proof. It remains to show that the weak solution to (3) is bounded in $C^{\alpha}(\Omega)$ uniformly in time. For $\tau \geq 0$, we define a smooth cut-off function $\varphi_{\tau} : \mathbb{R} \to [0,1]$ such that $\varphi_{\tau}|_{(-\infty,\tau]} = 0$, $\varphi_{\tau}|_{[\tau+1,\infty)} = 1$, and $|\varphi_{\tau}'| \leq C$ for C independent of τ . From the equations of (3), we get for $Z \in \{N, T, I, U\}$,

$$\begin{cases} \partial_t(\varphi_\tau Z) - \nabla \cdot (d_i \nabla Z) = \varphi_\tau' Z + \varphi_\tau F_i(N, T, I, U), & x \in \Omega, t > \tau, \\ \nabla_\nu(d_i \varphi_\tau Z) = 0, & x \in S, t > \tau, Z \in \{N, T, I\} \\ \nabla_\nu(d_U \varphi_\tau U) = v H(a_0 - N), & x \in S, t > \tau, \\ (\varphi_\tau Z)(x, \tau) = 0, & x \in \Omega. \end{cases}$$

Since the right hand sides of all equations are bounded uniformly-in-time in the L^{∞} -norm, one can use the De Giorgi-Nash-Moser theory to get (see e.g. [DiB93] Remark 1.1 page 17 and Theorem 1.3 page 78) for any $Z \in \{N, T, I, U\}$,

$$\sup_{t\in[\tau,\tau+1]} \|Z(t)\|_{C^{\alpha}(\bar{\Omega})} \leq C \|\varphi_{\tau}'Z + F_i(N,I,T,U)\|_{L^{\infty}(\Omega\times(\tau,\tau+1))} \leq C \quad \forall \tau \geq 1,$$

where the constant C is independent of τ . Therefore,

$$\limsup_{t\to\infty} \|Z(t)\|_{C^{\alpha}(\bar{\Omega})} < +\infty, \quad Z\in\{N,I,T,U\}.$$

Thanks to the compact embedding $C^{\alpha}(\overline{\Omega}) \hookrightarrow L^{\infty}_{+}(\Omega)$, we obtain the existence of a maximal attractor in $L^{\infty}_{+}(\Omega)$, see e.g. [Tem97].

Finally, we investigate in more detail the large time dynamics of the system when the injection rate decays and for each interval of treatment, the reproduction rate of tumor cells is small for certain amount of time. More precisely, we assume the following.

(H5) It is assumed that

$$\lim_{t o\infty}\|v(t)\|_{L^\infty(S)}=0,\quad \inf_{(x,t)}s(x,t)\geq eta>0,$$

and there are positive constants R_0 , L, $\xi \in (0, L)$, $K_0 \in \mathbb{N}$ such that for all $j \geq K_0$,

$$\sup_{x \in \Omega, \mathbf{Z} \in \mathbb{R}^4_+} |r_2(x, t, \mathbf{Z})| \le R_0 \quad \forall t \in (j\mathsf{L} - \xi, j\mathsf{L}).$$

The last condition in (H5) means that for each interval of treatment ((j-1)L, jL), the reproduction rate is required to be small only on an interval of size $\xi \in (0, L)$ which is $(jL - \xi, jL)$. This might be explained as the drug takes a certain time, namely the time interval $((j-1)L, jL - \xi)$, to start showing effect on the reproduction rate of tumor cells. Consequently, the number of tumor cells can grow, at most linearly (see Theorem 2.7), on the interval $((j-1)L, jL - \xi)$, but eventually decays to zero as $t \to \infty$. This is in fact consistent with Jeff's phenomenon ([DPR01]) mentioned in the introduction, see Figure 1.



Figure 1: The behavior of number of tumor cells, i.e. the L^1 -norm of T, (the blue dashed line) against its reproduction rate r_2 (the red solid line) in the time interval [0, 15]. Here we choose the treatment interval L = 1. The growth rate $r_2(x,t) \equiv r_2(t)$ depends continuous on time and is defined by: for each natural number $k \in \mathbb{N}$, r(t) = 1.1 for $k \leq t \leq k + 0.6$, $r(t) = 10^{-4}$ for $k + 0.7 \leq t \leq k + 1$, and r(t) is linear on (k + 0.6, k + 0.7). Here we notice the Jeff's phenomenon: the number of tumor cells grows in some intervals where the reproduction rate is large, but decays where the reproduction rate is small, and eventually the number of tumors decreases to 0.

Lemma 2.6. Assume (H1)–(H5) with A_1 in (H2) is time independent. Then for any $1 \le p < \infty$

$$\lim_{t \to \infty} \|U(t)\|_{L^p(\Omega)} = 0.$$

Proof. By multiplying the equation of U in (3) by U^{p-1} , $p \ge 2$, and using similar arguments as in Theorem 2.3 we obtain

$$\frac{d}{dt} \|U\|_{L^{p}(\Omega)}^{p} \leq -Cp(k_{0} - \|v(t)\|_{L^{\infty}(S)}) \|U\|_{L^{p}(\Omega)}^{p} + C\|v\|_{L^{\infty}(S)}.$$

By using Gronwall's lemma, then applying the decay of v in (H5) we obtain finally

$$\lim_{t\to\infty} \|U(t)\|_{L^p(\Omega)} = 0.$$

Finally, we show that the if the reproduction rate of the tumor cells is eventually small then they will decay to zero in large time.

Theorem 2.7. Assume (H1)–(H5) with A_1 in (H2) time independent. Assume moreover that $\inf_{\Omega} I_0(x) > 0$. Then there are positive constants R_* and $\tau_* = \tau_*(R_*)$ such that if R_0 in (H5) satisfies $R_0 < R_*$, then

$$||T(t)||_{L^{\infty}(\Omega)} \le Ce^{-\kappa t}, \quad \forall t \ge \tau_*$$

for some constants $C, \kappa > 0$.

Proof. From the equation of I in (3) and (H5),

$$\partial_t I - \nabla \cdot (d_3(x,t,I)\nabla I) + (r_3 b_3 I + c_1 T + k_1)I = s(x,t) + \frac{\rho IT}{\alpha + T} \ge \beta$$

for all $(x,t) \in \Omega \times (0,+\infty)$. Note that $r_3b_3I + c_1T + k_1$ is bounded uniformly in time and space. Let $d(x,t) = d_3(x,t,I)$, $R(x,t) = r_3b_3I + c_1T + k_1$, $G(x,t) = s(x,t) + \rho IT/(\alpha + T) \ge \beta > 0$, and $K = ||R||_{L^{\infty}(Q)}$. Suppose y(t) solves

$$y'(t) = \beta - Ky(t), \quad y(0) = 0.$$

Then the comparison principle implies

$$I(x,t) \ge y(t) \xrightarrow{t \to \infty} \frac{\beta}{K} > 0 \quad \text{ for all } x \in \Omega.$$

Thus

$$\liminf_{t \to \infty} \inf_{x \in \Omega} I(x, t) \ge \gamma > 0.$$
(12)

Turning to the equation of T in (3) on the time interval $((j-1)L, jL - \xi), j \ge K_0$, we have

$$\partial_t T \leq \nabla \cdot (d_2(x,t,T)\nabla T) + r_2(x,t,N,T,I,U)T.$$

Using the assumption that $r_2 \leq R_0$ uniformly in all variables, and thanks to Theorem 2.3,

$$\limsup_{t\to\infty}\|T(t)\|_{L^\infty(\Omega)}\leq\omega<+\infty$$

we can then use comparison principle to get

$$\|T(t)\|_{L^{\infty}(\Omega)} \leq \|T((j-1)\mathsf{L})\|_{L^{\infty}(\Omega)} + \omega R_0(t-(j-1)\mathsf{L}), \quad \forall t \in ((j-1)\mathsf{L}, j\mathsf{L}-\xi).$$

In particular, it holds

$$\|T(j\mathsf{L}-\xi)\|_{L^{\infty}(\Omega)} \le \|T((j-1)\mathsf{L})\|_{L^{\infty}(\Omega)} + \omega R_0(L-\xi) \quad \forall j \ge K_0 + 1.$$
(13)

For $t \in (jL - \xi, jL)$, we use (H5) and the lower bound (12) to get

$$\partial_t T \le \nabla \cdot (d_2(x,t,T)\nabla T) + (r_2 - c_2 I)T \le \nabla \cdot (d_2(x,t,T)\nabla T) + (R_0 - c_2 \gamma)T.$$

Therefore, for $R_0 < R_* := c_2 \gamma$, it follows that

$$\|T(t)\|_{L^{\infty}(\Omega)} \leq e^{-\delta_{*}(t-(j\mathsf{L}-\xi))} \|T(j\mathsf{L}-\xi)\|_{L^{\infty}(\Omega)}, \quad \forall t \in (j\mathsf{L}-\xi, j\mathsf{L}),$$

and in particular

$$\|T(j\mathsf{L})\|_{L^{\infty}(\Omega)} \le e^{-\delta_{*}\xi} \|T(j\mathsf{L}-\xi)\|_{L^{\infty}(\Omega)} \quad \forall j \ge K_{0}+1.$$
(14)

From (13) and (14) we obtain

$$||T(j\mathsf{L})||_{L^{\infty}(\Omega)} \le e^{-\delta_{*}\xi} ||T((j-1)\mathsf{L})||_{L^{\infty}(\Omega)} + e^{-\delta_{*}\xi} \omega R_{0}(L-\xi) \quad \forall j \ge K_{0}+1.$$

Thanks to this, for large enough L and ξ sufficiently close to L, we have

$$\|T(j\mathsf{L})\|_{L^{\infty}(\Omega)} \leq \frac{1}{2} \|T((j-1)\mathsf{L})\|_{L^{\infty}(\Omega)} \quad \forall j \geq K_0,$$

which implies the exponential decay of T(t) for large enough t > 0.

3 The optimal injection rate of chemotherapeutic drug

Throughout this section, we assume the nonnegative initial data for (3) is fixed and bounded. Let t_0 be a fixed time and fix a constant \mathcal{A}_0 which is larger than A_1 in (H2) for all \tilde{t} . We introduce an admissible set

$$U_{ad} = \{ v \in L^{\infty}(S \times (0, t_0)) \, | \, \mathcal{A}_0 \ge v(x, t) \ge 0 \text{ a.e. in } S \times (0, t_0) \} \,.$$

For each $v \in U_{ad}$, under assumptions in Theorem 2.3 there exists a unique bounded solution to (3), which allows us to define the solution map

$$S: U_{ad} \to (L^{\infty}(\Omega \times (0, t_0)))^4$$
$$v \mapsto S(v) = (N, T, I, U).$$

In the following, we will write S(v)(Z) = Z for $Z \in \{N, T, I, U\}$. Let

$$A_0 = \int_\Omega N_0(x) dx, \quad B_0 = \int_\Omega I_0(x) dx$$

where N_0 and I_0 are the given nonnegative initial data, and define

$$egin{aligned} A(t) &:= \int_\Omega \mathcal{S}(u)(N)(x,t)dx, \ B(t) &:= \int_\Omega \mathcal{S}(u)(I)(x,t)dx. \end{aligned}$$

During a chemotherapeutic drug treatment, one of the main goals is to find the optimal drug injection rate v(x,t) which will minimize the total amount of tumor cells at t_0 . This leads to an optimal control problem in which v(x,t) is the control variable.

For every $v \in U_{ad}$, we define the cost functional as follows:

$$J(v) = \int_{\Omega} \mathcal{S}(v)(T)(x,t_0) dx + \lambda \|v\|_{L^{\infty}(S \times (0,t_0))},$$

where $\lambda > 0$ is a given regularization parameter.

In practice, during a chemotherapeutic drug treatment for cancer patients, we have to make sure that the normal and immune cells maintain an acceptable level. Hence we impose the constraints

$$\int_\Omega N(x,t)dx \geq a_0 > 0 \quad ext{and} \quad \int_\Omega I(x,t)dx \geq b_0 > 0 ext{ for } t \in [0,t_0],$$

where $0 < a_0 < A_0$ and $0 < b_0 < B_0$. It is important to note that for given $t_0 > 0$, s(x,t) and the set of parameters and initial data in (3), it seems not possible to randomly select the values a_0 and b_0 above. As a result, we assume

(H6) a_0 and b_0 are values for which there exists at least one $v \in U_{ad}$ so that

$$\int_{\Omega} \mathcal{S}(v)(N)(x,t)dx \ge a_0 > 0 \quad \text{and} \quad \int_{\Omega} \mathcal{S}(v)(I)(x,t)dx \ge b_0 > 0 \text{ for } t \in [0,t_0].$$
(15)

Note that thanks to the continuity of solution in time, we can obtain (H6) if $t_0 > 0$ is sufficiently small.

Now we can state the following optimal control problem:

Find
$$u(x,t) \in U_{ad}$$
 such that
 $J(u; N, T, I, U) = \inf_{v(x,t) \in U_{ad}} J(v; N, T, I, U),$ (P)
subject to the constraint (15).

3.1 Existence of an optimal solution

The main result in this section is the following theorem.

Theorem 3.1. Let (**H1**)–(**H4**) and (**H6**) hold. Moreover, for any $z \in \mathbb{R}$, and any $\tilde{t} > 0$, the mapping $\Omega \times [0, \tilde{t}] \ni (x, t) \rightarrow d_i(x, t, z)$ is Hölder continuous in each component. Then there exists a function $u \in U_{ad}$ solving the optimal control problem (**P**).

Proof. Define

$$M_0 = \min\{a_0, b_0\} > 0.$$

Due to the constraint (15), we introduce an indicator function (penal function) $\beta(z)$:

$$eta(z) = \left\{ egin{array}{cc} 0, & ext{if } z \geq M_0 \ \infty, & ext{otherwise.} \end{array}
ight.$$

The indicator function will ensure that the drug injection will be stopped immediately once the amount of either normal cells or immune cells is below the acceptable level. Since the cost functional J is not

continuous, we make a smooth approximation with a small $\varepsilon > 0$, denoted by $\beta_{\varepsilon}(z)$, for the indicator function $\beta(z)$ by defining a smooth nonincreasing convex function $\beta_{\varepsilon}(z)$ on $[0, \infty)$ such that $\beta_{\varepsilon}(z) = 0$ if $z \ge M_0 + \varepsilon$ and $\beta_{\varepsilon}(M_0) = \frac{1}{\varepsilon}$. Consider the following approximate cost functional:

$$\widetilde{J}(v; N, T, I, U) := J(v; N, T, I, U) + \beta_{\varepsilon} \left(\inf_{t \in [0, t_0]} \left\{ \int_{\Omega} N(x, t) dx, \int_{\Omega} I(x, t) dx \right\} \right)$$

The cost functional $\tilde{J}(v; N, T, I, U)$ is nonnegative, but not necessarily convex. However, we can still define

$$J_0 = \inf_{v \in U_{ad}} \tilde{J}(v; N, T, I, U).$$

From (H6), we know each J_0 is finite as long as the constrain condition is satisfied. In addition, the construction of β_{ε} implies that for each $n \in \mathbb{N}$ there exists $u_n \in U_{ad}$ such that

$$J_0 \le \tilde{J}(u_n; N, T, I, U) \le J_0 + 1/n,$$

where we choose $\varepsilon = \frac{1}{n}$. As a result,

$$J(u_n; N, T, I, U) = \tilde{J}(u_n; N, T, I, U)$$

for all $n \in \mathbb{N}$. Let N_n, T_n, I_n, U_n be the solution to (3) associated with $v = u_n$. The results of the previous section imply this set $\{(N_n, T_n, I_n, U_n) | n \in \mathbb{N}\}$ is componentwise nonnegative and uniformly sup norm bounded, and the constrain (15) is satisfied for all $n \in \mathbb{N}$. Moreover,

$$\lim_{n \to \infty} J(u_n; N_n, T_n, I_n, U_n) = J_0$$

Now, due to the construction of \tilde{J} we know the functions u_n are uniformly sup norm bounded. Therefore, there exists a function $u(x,t) \in L^{\infty}(S_{t_0})$ such that

$$u_n \rightharpoonup u$$
 weakly in $L^2(S_{t_0})$

and

$$u_n \stackrel{*}{\rightharpoonup} u \quad \text{weakly-* in } L^{\infty}(S_{t_0}).$$

So, similar to the proof of Corollary 2.5 in the previous section, we know the sequence $\{(N_n, T_n, I_n, U_n)\}$ is bounded in $C^{\alpha,\alpha/2}(\bar{\Omega} \times [0, t_0])$, which is compactly embedded in $C(\bar{\Omega} \times [0, t_0])$. Therefore, there exists a subsequence, still denoted by (N_n, T_n, I_n, U_n) , which converges to a limit (N^*, T^*, I^*, U^*) in $C(\bar{\Omega} \times [0, t_0])$ with respect to the sup norm. Consequently,

$$F_i(N_n, T_n, I_n, U_n) \to F_i(^*N, T^*, I^*, U^*)$$
 in $C(\Omega \times [0, t_0])$ as $n \to \infty_{\mathcal{H}}$

for each i = 1, 2, 3, 4. Note that a weak solution for $U_n(x, t)$ in Q_{t_0} satisfies the following integral identity:

$$\int_0^{t_0} \int_{\Omega} [-U_n w_t + d_4 \nabla U_n \cdot \nabla w] dx dt + \int_0^{t_0} \int_S u_n H(N_n - a_0) w d\mathcal{H} d\tau$$
$$= \int_0^{t_0} \int_{\Omega} F_4(N_n, T_n, I_n U_n) w dx dt + \int_{\Omega} U_0(x) w(x, 0) dx,$$

for all test function $w(x,t) \in H^1(0,t_0;L^2(\Omega)) \cap L^2(0,t_0;H^1(\Omega))$ with $w(x,t_0) = 0$. Since

$$\begin{split} \nabla U_n &\rightharpoonup \nabla U^*, \qquad \text{weakly in } L^2(Q_{t_0}); \\ F_4(N_n, T_n, I_n, U_n) &\to F_4(N^*, T^*, I^*, U^*), \qquad \text{strongly in } L^1(Q_{t_0}) \end{split}$$

It follows that $U^*(x,t)$ is a weak solution to the equation of U in (3). Thus, we see the boundary condition (5) for U^* is satisfied. Similarly, the other boundary condition is also satisfied. Consequently, we see that (N^*, T^*, I^*, U^*) is a weak solution of the system (3)–(5) corresponding to the limit control u(x,t). This concludes the proof of the existence of an optimal control function u(x,t).

3.2 The first-order optimality condition

In this section we will derive the optimality condition. The crucial step is to find the Gateaux derivatives of the the cost function J and the solution map S with respect to the injection rate v(x,t). In order to do that, we first show that the solution map S is continuous provided the diffusion coefficients are Hölder continuous

Lemma 3.2. Assume (H1)–(H4), and the mapping $\Omega \times [0, \tilde{t}] \ni (x, t) \to d_i(x, t, z)$ is Hölder continuous in each component for any $z \in \mathbb{R}$ and any $\tilde{t} > 0$. Then the solution map S is continuous from U_{ad} to $(L^{\infty}(\Omega \times (0, t_0)))^4$.

Proof. Let $\{u_n\}_{n\geq 1}$ be a sequence in U_{ad} such that $u_n \to u$ in $L^{\infty}(\Omega \times (0, t_0))$. Denote by $(N_n, T_n, I_n, U_n) = S(u_n)$. Similarly to the proof of Theorem 3.1, there is a subsequence $\{n_k\} \subset \{n\}$ such that

$$(N_{n_k}, T_{n_k}, I_{n_k}, U_{n_k}) \xrightarrow{n_k \to \infty} (N^*, T^*, I^*, U^*) \quad \text{in } (L^{\infty}(\Omega \times (0, t_0)))^4$$

where $(N^*, T^*, I^*, U^*) = S(u)$. Thanks to the Hölder continuity of the coefficients, we can apply Theorem 2.3 to get the uniqueness of (N^*, T^*, I^*, U^*) , and therefore, we have the convergence of the whole sequence $\{(N_n, T_n, I_n, U_n)\}_{n\geq 1}$. This is precisely the continuity of the solution map S and the proof is complete.

Suppose $u(x,t) \in U_{ad}$ is the optimal control and (N,T,I,U) is the corresponding solution of the system (3), i.e. (N,T,I,U) = S(u). Let

$$w(x,t) = u(x,t) + \varepsilon v(x,t) \in U_{ad}, \qquad \forall \varepsilon \ge 0.$$

Thanks to the continuity of S, we can choose ε sufficiently small such that the constrain (15) holds. Using similar arguments in the proof of Theorem 3.1, we get

$$\lim_{\varepsilon \to 0} (N_{\varepsilon}, T_{\varepsilon}, I_{\varepsilon}, U_{\varepsilon}) = (N, T, I, U)$$

in the weak sense of $V_2(Q_{t_0})$ and strongly in $L^2(Q_{t_0})$. Define

$$\hat{N} = rac{N-N_{arepsilon}}{arepsilon}, \quad \hat{T} = rac{T-T_{arepsilon}}{arepsilon}, \quad \hat{I} = rac{I-I_{arepsilon}}{arepsilon}, \quad \hat{U} = rac{U-U_{arepsilon}}{arepsilon}.$$

After a routine calculation, we see that $(\hat{N}, \hat{T}, \hat{I}, \hat{U})$ satisfies the following system in the weak sense:

$$\hat{N}_{t} - \nabla[d_{1}\nabla\hat{N}] = \frac{\partial F_{1}}{\partial N}(\theta_{N}^{1})\hat{N} + \frac{\partial F_{1}}{\partial T}(\theta_{T}^{1})\hat{T} + \frac{\partial F_{1}}{\partial I}(\theta_{I}^{1})\hat{I} + \frac{\partial F_{1}}{\partial U}(\theta_{U}^{1})\hat{U},$$

$$\hat{T}_{t} - \nabla[d_{2}\nabla\hat{T}] = \frac{\partial F_{2}}{\partial N}(\theta_{N}^{2})\hat{N} + \frac{\partial F_{2}}{\partial T}(\theta_{T}^{2})\hat{T} + \frac{\partial F_{2}}{\partial I}(\theta_{I}^{2})\hat{I} + \frac{\partial F_{1}}{\partial U}(\theta_{U}^{2})\hat{U},$$

$$\hat{I}_{t} - \nabla[d_{3}\nabla\hat{I}] = \frac{\partial F_{3}}{\partial N}(\theta_{N}^{3})\hat{N} + \frac{\partial F_{3}}{\partial T}(\theta_{T}^{3})\hat{T} + \frac{\partial F_{3}}{\partial I}(\theta_{I}^{3})\hat{I} + \frac{\partial F_{3}}{\partial U}(\theta_{U}^{3})\hat{U},$$

$$\hat{U}_{t} - \nabla[d_{4}\nabla\hat{U}] = \frac{\partial F_{4}}{\partial N}(\theta_{N}^{4})\hat{N} + \frac{\partial F_{4}}{\partial T}(\theta_{T}^{4})\hat{T} + \frac{\partial F_{4}}{\partial I}(\theta_{I}^{4})\hat{I} + \frac{\partial F_{4}}{\partial U}(\theta_{U}^{4})\hat{U},$$
(16)

where θ_Z^j is in between Z and Z_{ε} for $Z \in \{N, T, I, U\}$. Moreover, $(\hat{N}, \hat{T}, \hat{I}, \hat{U})$ satisfies the initial and boundary conditions

$$(\hat{N}, \hat{T}, \hat{I}, \hat{U})|_{t=0} = (0, 0, 0, 0), \qquad x \in \Omega, \nabla_{\nu}(\hat{N}, \hat{T}, \hat{I}) = (0, 0, 0), \qquad (x, t) \in S \times (0, t_0), d_4 \nabla_{\nu} \hat{U} = v(x, t) H(N_{\varepsilon} - a_0) + u H'(\theta) \hat{N},$$
 (17)

where H' is the derivative of H and, θ is a mean-value between $N - a_0$ and $N_{\varepsilon} - a_0$. Thanks to the boundedness of Z and Z_{ε} , $Z \in \{N, T, I, U\}$, we have for i = 1, 2, 3, 4,

$$\frac{\partial F_i}{\partial N}(\theta_N^i), \ \frac{\partial F_i}{\partial T}(\theta_T^i), \ \frac{\partial F_i}{\partial I}(\theta_I^i), \ \frac{\partial F_i}{\partial U}(\theta_U^i)$$

are all bounded. We can use the energy method to obtain

$$\|\hat{N}\|_{V_2(Q_{t_0})} + \|\hat{T}\|_{V_2(Q_{t_0})} + \|\hat{I}\|_{V_2(Q_{t_0})} + \|\hat{U}\|_{V_2(Q_{t_0})} \le C,$$

where C depends only on known data, but not on ε . The compactness argument implies that there exists (N^*, T^*, I^*, U^*) such that, up to a subsequence,

$$\lim_{\varepsilon \to 0} (\hat{N}, \hat{T}, \hat{I}, \hat{U}) = (N^*, T^*, I^*, U^*) \quad \text{strongly in } L^2(\Omega \times (0, t_0)).$$

It follows from $H'(\theta) = \int_0^1 H'(\tau N_{\varepsilon} + (1-\tau)N - a_0)d\tau$ that

$$\lim_{\varepsilon \to 0} H'(\theta) = H'(N - a_0) \quad \text{ in } L^2(S \times (0, t_0)).$$

We summarize the above derivation to obtain the following optimality condition.

Theorem 3.3. Let u(x,t) be the optimal injection rate and (N,T,I,U) is the corresponding solution of the system (3). Then for any $v(x,t) \in U_{ad}$, there exists a vector function (N^*,T^*,I^*,U^*) which is a weak solution to the linear system (16)–(17) with the last condition in (17) replaced by

$$d_4 \nabla_{\nu} U^* = v(x, t) H(N - a_0) + u H'(N - a_0) N^*.$$

4 Conclusion

In this paper we studied a reaction-diffusion system arising from a cancer treatment, where the drug is injected from the boundary of the domain under the condition that number of normal cells is above a certain level. We first show the global existence of a unique bounded weak solution by using energy method, then show that there exists a maximal attractor. Moreover, if the reproduction rate of tumor cells is eventually small, then it is proved that they die out in large time, despite possible temporal increasing due to Jeff's phenomenon. Finally, an optimal control problem is posed with the aim of finding the optimal dosage of the drug is investigated. By a penalty method, we showed the existence of an optimal solution. This result could be potentially used by medical practitioners to design an automatic drug deliver device during a tumor treatment for patients. More study with clinical data is needed for potential applications in clinics, for instance the presence of Jeff's phenomenon or numerical simulations with real clinical data.

Acknowledgement. B.Q. Tang received funding from the FWF project "Quasi-steady-state approximation for PDE", number I-5213. This work is partially supported by NAWI Graz.

A Proof of Lemma 2.2

The proof uses the ideas from [Ali79]. For $k \in \mathbb{N}$, multiplying (6) by $u^{2^{k-1}}$ leads to

$$\begin{aligned} \frac{1}{2^{k}} \frac{d}{dt} \int_{\Omega} u^{2^{k}} dx &+ \frac{2^{k} - 1}{2^{2k - 2}} \delta_{0} \int_{\Omega} \left| \nabla(u^{2^{k - 1}}) \right|^{2} dx \\ &\leq a \int_{\Omega} u^{2^{k}} dx + b \int_{\Omega} u^{2^{k} - 1} dx + c \int_{S} u^{2^{k}} d\mathcal{H} + \|d\|_{L^{\infty}(S \times (0, T))} \int_{S} u^{2^{k} - 1} d\mathcal{H}. \end{aligned}$$

Using

$$b \int_{\Omega} u^{2^{k}-1} dx \leq \frac{b|\Omega|}{2^{k}} + \frac{b(2^{k}-1)}{2^{k}} \int_{\Omega} u^{2^{k}} dx,$$
$$\|d\|_{L^{\infty}(S \times (0,T))} \int_{S} u^{2^{k}-1} d\mathcal{H} \leq \frac{|S| \|d\|_{L^{\infty}(S \times (0,t_{0}))}}{2^{k}} + \frac{\|d\|_{L^{\infty}(S \times (0,t_{0}))}(2^{k}-1)}{2^{k}} \int_{S} u^{2^{k}} d\mathcal{H},$$

we get

$$\frac{1}{2^k}\frac{d}{dt}\int_{\Omega} u^{2^k}dx + \frac{2^k - 1}{2^{2k-2}}\delta_0 \int_{\Omega} \left|\nabla(u^{2^{k-1}})\right|^2 dx \le C_0 \int_{\Omega} u^{2^k}dx + C_1 \int_{S} u^{2^k}d\mathcal{H} + \frac{C_2}{2^{k-1}}\delta_0 \int_{\Omega} \left|\nabla(u^{2^{k-1}})\right|^2 dx \le C_0 \int_{\Omega} u^{2^k}dx + C_1 \int_{S} u^{2^k}d\mathcal{H} + \frac{C_2}{2^{k-1}}\delta_0 \int_{\Omega} \left|\nabla(u^{2^{k-1}})\right|^2 dx \le C_0 \int_{\Omega} u^{2^k}dx + C_1 \int_{S} u^{2^k}d\mathcal{H} + \frac{C_2}{2^{k-1}}\delta_0 \int_{\Omega} \left|\nabla(u^{2^{k-1}})\right|^2 dx \le C_0 \int_{\Omega} u^{2^k}dx + C_1 \int_{S} u^{2^k}d\mathcal{H} + \frac{C_2}{2^{k-1}}\delta_0 \int_{\Omega} \left|\nabla(u^{2^{k-1}})\right|^2 dx \le C_0 \int_{\Omega} u^{2^k}dx + C_1 \int_{S} u^{2^k}d\mathcal{H} + \frac{C_2}{2^{k-1}}\delta_0 \int_{\Omega} \left|\nabla(u^{2^{k-1}})\right|^2 dx \le C_0 \int_{\Omega} u^{2^k}dx + C_1 \int_{S} u^{2^k}d\mathcal{H} + \frac{C_2}{2^{k-1}}\delta_0 \int_{\Omega} \left|\nabla(u^{2^{k-1}})\right|^2 dx \le C_0 \int_{\Omega} u^{2^k}dx + C_1 \int_{S} u^{2^k}d\mathcal{H} + \frac{C_2}{2^{k-1}}\delta_0 \int_{\Omega} u^{2^k}d\mathcal{H} + C_1 \int_{S} u^{2^k}d\mathcal{H} + C_1$$

where C_0, C_1, C_2 depend only on $a, b, c, |\Omega|, |S|$ and $||d||_{L^{\infty(S \times (0, t_0))}}$. It follows from this

$$\frac{1}{2}\frac{d}{dt}\int_{\Omega}u^{2^{k}}dx + \delta_{0}\int_{\Omega}\left|\nabla(u^{2^{k-1}})\right|^{2}dx \le C_{0}2^{k-1}\int_{\Omega}u^{2^{k}}dx + C_{1}2^{k-1}\int_{S}u^{2^{k}}d\mathcal{H} + C_{2}.$$

Denote by $u_k := u^{2^{k-1}}$ and $C_k := \max\{C_0, C_1\}2^{k-1}$ we get

$$\frac{1}{2}\frac{d}{dt}\int_{\Omega}u_k^2dx + \delta_0\int_{\Omega}|\nabla u_k|^2dx \le C_k\int_{\Omega}|u_k|^2dx + C_k\int_{S}|u_k|^2d\mathcal{H} + C_2.$$
(18)

By the Gagliardo-Nirenberg inequality, for any $\varepsilon_0 > 0$, it holds

$$\int_{\Omega} |v|^2 dx \leq \varepsilon_0 \int_{\Omega} |\nabla v|^2 dx + C_{\Omega,n} \varepsilon_0^{-n/2} \left(\int_{\Omega} |v| dx \right)^2,$$

for some $C_{\Omega,n}$ depending only on Ω and n. We combine this with the trace interpolation inequality for any $\varepsilon > 0$

$$\begin{split} \int_{S} |v|^{2} d\mathcal{H} &\leq \varepsilon \int_{\Omega} |\nabla v|^{2} dx + \frac{C_{\Omega,n}}{\varepsilon} \int_{\Omega} |v|^{2} dx \\ &\leq \left(\varepsilon + \frac{C_{\Omega,n}\varepsilon_{0}}{\varepsilon}\right) \int_{\Omega} |\nabla v|^{2} dx + \frac{C_{\Omega,n}^{2}\varepsilon_{0}^{-n/2}}{\varepsilon} \left(\int_{\Omega} |v| dx\right)^{2}. \end{split}$$

Now we choose

$$arepsilon = rac{\delta_0}{8}C_k^{-1} \quad ext{and } arepsilon_0 \leq rac{\delta_0arepsilon}{8C_{\Omega,n}C_k} = \left(rac{\delta_0}{8}
ight)^2rac{1}{C_{\Omega,n}}C_k^{-2}.$$

Note that by enlarging $C_{\Omega,n}$ sufficiently, we have $\varepsilon_0 C_k \leq \frac{\delta_0}{4}$. Therefore

$$C_k \int_{\Omega} |u_k|^2 dx + C_k \int_{S} |u_k|^2 d\mathcal{H} \leq \frac{\delta_0}{4} \int_{\Omega} |\nabla u_k|^2 dx + C_{\Omega,n} \left(C_k^{n+1} + C_k^{n+2} \right) \left(\int_{\Omega} |u_k| dx \right)^2 + C_2 \left(\int_{\Omega} |u_k|^2 d\mathcal{H} \right)^2 +$$

Thus we have

$$\frac{1}{2}\frac{d}{dt}\int_{\Omega}|u_{k}|^{2}dx + \frac{\delta_{0}}{2}\int_{\Omega}|\nabla u_{k}|^{2}dx \leq \widehat{C}_{k}\left(\int_{\Omega}|u_{k}|dx\right)^{2} + C_{2}$$

where $\hat{C}_k \sim (2^{n+2})^k$. Adding both sides with $(\delta_0/2) \int_{\Omega} |u_k|^2 dx$ and using the Gagliardo-Nirenberg inequality again, we arrive at

$$\frac{d}{dt}\int_{\Omega}|u_{k}|^{2}dx+\delta_{0}\int_{\Omega}|u_{k}|^{2}dx\leq\widetilde{C}_{k}\left(\int_{\Omega}|u_{k}|dx\right)^{2}+C_{2}$$

with $\tilde{C}_k \sim (2^{n+2})^k$. An application of the classical Gronwall inequality yields for any $t \in (0, t_0)$

$$\begin{split} \int_{\Omega} |u_k(t)|^2 dx &\leq e^{-\delta_0 t} \int_{\Omega} |u_k(0)|^2 dx + \widetilde{C}_k \int_0^t e^{-\delta_0(t-s)} \left(\int_{\Omega} |u_k(s)| dx \right)^2 ds + \frac{C_2}{\delta_0} \\ &\leq \int_{\Omega} |u_k(0)|^2 dx + \frac{\widetilde{C}_k}{\delta_0} \left(\sup_{s \in (0,t_0)} \int_{\Omega} |u_k(s)| dx \right)^2 + \frac{C_2}{\delta_0}. \end{split}$$

Replacing $u_k = u^{2^{k-1}}$ again, and taking the root of order 2^k we obtain

$$\left(\sup_{t \in (0,t_0)} \int_{\Omega} u^{2^k}(t) dx\right)^{1/2^k} \le \left(\int_{\Omega} |u_0|^{2^k} dx + \frac{\widetilde{C}_k}{\delta_0} \left(\sup_{s \in (0,t_0)} \int_{\Omega} u^{2^{k-1}}(s) dx\right)^2 + \frac{C_2}{\delta_0}\right)^{1/2^k}$$

By denoting Q_k the left hand side of this inequality, we get

$$Q_k \le \left(\|u_0\|_{L^{\infty}}^{2^k} |\Omega| + \frac{\widetilde{C}_k}{\delta_0} Q_{k-1}^{2^k} + \frac{C_2}{\delta_0} \right)^{1/2^k}$$

Thus, with $C_3 = |\Omega| + \delta_0^{-1} + C_2 \delta_0^{-1} + 1$, we have

$$\max\{Q_k, \|u_0\|_{L^{\infty}(\Omega)}, 1\} \le \max\{Q_{k-1}, \|u_0\|_{L^{\infty}(\Omega)}, 1\}C_3^{1/2^k}\widetilde{C}_k^{1/2^k}.$$

Thus, by $\widetilde{C}_k \sim (2^{n+2})^k$

$$\begin{split} \max\{Q_k, \|u_0\|_{L^{\infty}(\Omega)}, 1\} &\leq \max\{Q_0, \|u\|_{L^{\infty}(\Omega)}, 1\} \prod_{k=1}^{\infty} C_3^{1/2^k} \widetilde{C}_k^{1/2^k} \\ &\leq C \max\{\|u\|_{L^{\infty}(0, t_0; L^1(\Omega))}; \|u_0\|_{L^{\infty}(\Omega)}; 1\} C_3^{\sum_{k \geq 1} (1/2^k)} (2^{n+2})^{\sum_{k \geq 1} (k/2^k)} \\ &\leq C_4 \max\{\|u\|_{L^{\infty}(0, t_0; L^1(\Omega))}; \|u_0\|_{L^{\infty}(\Omega)}; 1\} \end{split}$$

with C_4 depending only on a, b, c, $||d||_{L^{\infty}(S \times (0,T))}$, Ω and n. Letting $k \to \infty$, we obtain finally the desired estimate of the lemma.

References

- [Ada93] John A Adam. The dynamics of growth-factor-modified immune response to cancer growth: One dimensional models. *Mathematical and Computer modelling*, 17(3):83–106, 1993.
- [Ali79] Nicholas D Alikakos. An application of the invariance principle to reaction-diffusion equations. Journal of Differential Equations, 33(2):201–225, 1979.
- [ASR17] Fatemeh Ansarizadeh, Manmohan Singh, and David Richards. Modelling of tumor cells regression in response to chemotherapeutic treatment. Applied Mathematical Modelling, 48:96–112, 2017.
- [ATH⁺24] Hannah G. Anderson, Gregory P. Takacs, Duane C. Harris, Yang Kuang, Jeffrey K. Harrison, and Tracy L. Stepien. Global stability and parameter analysis reinforce therapeutic targets of PD-L1-PD-1 and MDSCs for glioblastoma. *Journal of Mathematical Biology*, 88(10):33 pages, 2024.
- [BP00] Nicola Bellomo and Luidgi Preziosi. Modelling and mathematical problems related to tumor evolution and its interaction with the immune system. *Mathematical and Computer Modelling*, 32(3-4):413–452, 2000.
- [CSS92] Joseph J Casciari, Stratis V Sotirchos, and Robert M Sutherland. Mathematical modelling of microenvironment and growth in EMT6/Ro multicellular tumour spheroids. *Cell* proliferation, 25(1):1–22, 1992.
- [DiB93] E DiBenedetto. Degenerate Parabolic Equations. Springer-Verlag, 1993.
- [DPR01] Lisette G De Pillis and Ami Radunskaya. A mathematical tumor model with immune resistance and drug therapy: an optimal control approach. *Computational and Mathematical Methods in Medicine*, 3(2):79–100, 2001.
- [DPR03] Lisette G De Pillis and Ami Radunskaya. The dynamics of an optimally controlled tumor model: A case study. *Mathematical and computer modelling*, 37(11):1221–1244, 2003.
- [ESJY21] Nikolopoulou Elpiniki, E. Eikenberry Steffen, L. Gevertz Jana, and Kuang Yang. Mathematical modeling of an immune checkpoint inhibitor and its synergy with an immunostimulant. Discrete and Continuous Dynamical Systems - B, 26(4):2133-2159, 2021.
- [Eva10] Lawrence C Evans. *Partial Differential Equations*, volume 19. American Mathematical Soc., 2010.
- [FGP99] Bruno Firmani, Luciano Guerri, and Luigi Preziosi. Tumor/immune system competition with medically induced activation/deactivation. Mathematical Models and Methods in Applied Sciences, 9(04):491–512, 1999.
- [FK11] Avner Friedman and Yangjin Kim. Tumor cells proliferation and migration under the influence of their microenvironment. *Mathematical Biosciences and Engineering*, 8(2):371– 383, 2011.

- [Fri05] Avner Friedman. Cancer models and their mathematical analysis. In *Tutorials in Mathematical Biosciences III: Cell Cycle, Proliferation, and Cancer*, pages 223–246. Springer, 2005.
- [Jac15] Trachette L. Jackson. Dynamics of cancer: mathematical foundations of oncology [book review of MR3309233]. SIAM Rev., 57(1):161–162, 2015.
- [KMTP94] Vladimir A Kuznetsov, Iliya A Makalkin, Mark A Taylor, and Alan S Perelson. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bulletin of mathematical biology, 56(2):295–321, 1994.
- [KP98] Denise Kirschner and John Carl Panetta. Modeling immunotherapy of the tumor-immune interaction. *Journal of mathematical biology*, 37:235–252, 1998.
- [LF17] Lai and A Friedman. Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model. *PLoS ONE*, 12(5):e0178479, 2017.
- [LFJ⁺09] John S Lowengrub, Hermann B Frieboes, Fang Jin, Yao-Li Chuang, Xiangrong Li, Paul Macklin, Steven M Wise, and Vittorio Cristini. Nonlinear modelling of cancer: bridging the gap between cells and tumours. *Nonlinearity*, 23(1):R1, 2009.
- [Lie96] Gary M Lieberman. Second order parabolic differential equations. World scientific, 1996.
- [LN96] Yuan Lou and Wei-Ming Ni. Diffusion, self-diffusion and cross-diffusion. Journal of Differential Equations, 131(1):79–131, 1996.
- [LSU68] Olga Aleksandrovna Ladyzhenskaia, Vsevolod Alekseevich Solonnikov, and Nina N Ural'tseva. Linear and quasi-linear equations of parabolic type, volume 23. American Mathematical Soc., 1968.
- [Nit13] Robin Nittka. Quasilinear elliptic and parabolic robin problems on lipschitz domains. Nonlinear Differential Equations and Applications NoDEA, 20(3):1125–1155, 2013.
- [OS99] Markus R Owen and Jonathan A Sherratt. Mathematical modelling of macrophage dynamics in tumours. *Mathematical Models and Methods in Applied Sciences*, 9(04):513–539, 1999.
- [RCM07] Tiina Roose, S Jonathan Chapman, and Philip K Maini. Mathematical models of avascular tumor growth. SIAM review, 49(2):179–208, 2007.
- [Tem97] Roger Temam. Infinite-dimensional dynamical systems in mechanics and physics, volume 68 of Applied Mathematical Sciences. Springer-Verlag, New York, second edition, 1997.
- [Yin22] Hong-Ming Yin. On a mathematical model arising from an optimal chemotherapeutic drug treatment for tumor cells. *arXiv:2212.05146*, 2022.